In silico cancer modeling: is it ready for prime time?
At the dawn of the era of personalized, systems-driven medicine, computational or in silico modeling and the simulation of disease processes is becoming increasingly important for hypothesis generation and data integration in both experiments and clinics alike. Arguably, the use of these techniques is nowhere more visible than in oncology. To illustrate the field's vast potential, as well as its current limitations, we briefly review selected studies on modeling malignant brain tumors. Implications for clinical practice, and for clinical trial design and outcome prediction, are also discussed.
Complex Biosystems Modeling Laboratory, Harvard-MIT Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital-East, 13th Street, Charlestown, MA 02129, USA. deisboec@helix.mgh.harvard.edu
Thomas S
TS
Deisboeck
Le
L
Zhang
Jeongah
J
Yoon
Jose
J
Costa
D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D003198:Computer Simulation; D017076:Computer-Aided Design; D006801:Humans; D010597:Pharmacogenetics; D012107:Research Design / Q000592:standards*; D049490:Systems Biology